You are on page 1of 1

In the 2016 European guidelines for treatment

of heart failure, mineralocorticoid antagonists


(MRA) are indicated in
A. As start therapy
B. When patients are symptomatic despite
ACEI and B blockers and LVEF < 45%
C. When patients are symptomatic despite
ACEI and B blockers and LVEF < 35%
D. All of the above

You might also like